Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Medicine

Immunology

Internal Medicine

Ophthalmology

Infectious Diseases

Show all topics

DOI

10.1016/s0140-6736(21)01699-8

License

CC-BY

Other Formats

PDF